SCFβ-TRCPsuppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SCFβ-TRCPsuppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 7, Pages 1289-1307
Publisher
Rockefeller University Press
Online
2012-06-19
DOI
10.1084/jem.20112446
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
- (2011) Debyani Chakravarty et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeted therapies for thyroid tumors
- (2011) Steven I Sherman MODERN PATHOLOGY
- PEST Motif Serine and Tyrosine Phosphorylation Controls Vascular Endothelial Growth Factor Receptor 2 Stability and Downregulation
- (2011) R. D. Meyer et al. MOLECULAR AND CELLULAR BIOLOGY
- Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic Frontier
- (2011) Matthew D. Ringel THYROID
- Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase
- (2010) Hiroyuki Inuzuka et al. CANCER CELL
- Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
- (2010) S. M. Keefe et al. CLINICAL CANCER RESEARCH
- Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCF -TrCP by single substrate depletion
- (2010) N. Kanarek et al. GENES & DEVELOPMENT
- BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus
- (2010) Dingxie Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
- (2010) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Vascular Aging: New Perspectives
- (2010) Z. Ungvari et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- B-RafV600E and thrombospondin-1 promote thyroid cancer progression
- (2010) C. Nucera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development
- (2010) Y. He et al. Science Signaling
- Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
- (2009) Jeffrey A Knauf et al. CURRENT OPINION IN CELL BIOLOGY
- Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis
- (2009) Cristina Rodríguez-Antona et al. ENDOCRINE-RELATED CANCER
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started